Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova最新文献

{"title":"[Depression Anxiety Stress Scale (russian language version)].","authors":"I M Fattakhov, E A Gorobets, I Kh Khairullin, R G Esin","doi":"10.17116/jnevro2025125051103","DOIUrl":"https://doi.org/10.17116/jnevro2025125051103","url":null,"abstract":"<p><strong>Objectives: </strong>Development and psychometric validation of the Russian version of the Depression Anxiety Stress Scale (DASS).</p><p><strong>Material and methods: </strong>The study included three stages: 1) direct and reverse translations, linguistic validation of the scale; 2) assessment of internal consistency, reliability, and sensitivity; and 3) psychometric validation of the scale in a sample of 250 Russian-speaking patients of a medical hospital (neurological, cardiological, therapeutic profiles) with signs of emotional disorders, as well as in a control sample of 100 Russian-speaking respondents without emotional disorders.</p><p><strong>Results: </strong>The severity of depression, anxiety, and stress in the Russian version of DASS correlated (<i>p</i><0.05) with the indicators of corresponding subscales in the valid Russian version of the Hospital Anxiety and Depression Scale (HADS) among patients of the medical hospital (neurological, cardiological, and therapeutic profiles) with signs of emotional disorders, while it did not correlate (<i>p</i>>0.05) with the indicators of the control group of respondents without emotional disorders.</p><p><strong>Conclusion: </strong>The Russian version of the Depression Anxiety Stress Scale is valid, has the required psychometric properties, and can be used in clinical practice to detect depression, anxiety, and stress. A study of the scale sensitivity in patients during drug therapy showed its efficacy for assessing the course of the disease and the effect of therapy.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 5","pages":"103-107"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Identification of depression biomarkers: Prospects for use in clinical practice].","authors":"S A Kashchenko, K A Kormachenko, M G Musaelyan, D V Galenko, A N Salakhova","doi":"10.17116/jnevro202512505151","DOIUrl":"https://doi.org/10.17116/jnevro202512505151","url":null,"abstract":"<p><p>Major depressive disorder (MDD) is one of the most common mental illnesses that poses a serious threat to public health. MDD is associated with various biological changes, such as increased inflammation, oxidative stress, dysregulation of the stress axis, and changes in growth factors. These changes may be used as potential biomarkers to facilitate more accurate diagnosis and effective treatment of depression. Recently, a growing interest has been in identifying biomarkers that could be objective indicators of the patient's condition, opening up new horizons for diagnosis and treatment and allowing a more personalized approach to each patient. This review covers current studies on biomarkers that can objectively indicate the patient's condition. Particular attention is paid to methods for detecting these biological markers and their prospects in clinical practice, including diagnosis, monitoring the effectiveness of therapy, and predicting relapses. Such approaches can significantly improve the treatment outcomes and quality of life of patients with depression.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 5","pages":"51-55"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology].","authors":"I V Litvinenko, A Yu Emelin, V Yu Lobzin, K M Naumov, I Yu Chapliev, G Yu Chapliev, N V Tsygan, A V Ryabtsev","doi":"10.17116/jnevro202512506113","DOIUrl":"https://doi.org/10.17116/jnevro202512506113","url":null,"abstract":"<p><strong>Objective: </strong>Is to develop a method for comprehensive assessment of fixation eye movements in patients with cognitive impairment.</p><p><strong>Material and methods: </strong>The study uses the Pupil Invisible eye-tracker. Using the PsychoPy software, a sequence of visual stimuli with audio and text accompaniment was created. Two consecutive tasks were set for the subjects: passive examination and memorization of images and search for a specific element on the presented image. To assess the experiment, we reviewed the entire testing record with all events occurring during the test.</p><p><strong>Results: </strong>It was found that the standard method of evaluating test results by viewing and analyzing video recordings was unacceptably time-consuming for the researcher. The large volume of obtained results and the lack of standard calculation methods complicated the mathematical processing, so additional software using Wolfram and Python was developed. A unique feature of the developed technique is the division of the constructed heat map based on the fixation movements of the eyes into a certain number of zones, which is achieved by calculating the area of a particular sector of the image related to the total area of the stimulus when performing the task. The experimental verification of the model revealed a «disorderly» direction of gaze without fixing the specified image, an increase in the size of the «heat» spot in a patient diagnosed with primary amnesic aphasia, which differed from those indicators of healthy individuals.</p><p><strong>Conclusion: </strong>As part of the study, a method was developed for assessing integrative indicators of eyeball movements, which may reflect the state of cognitive functions. In the second stage of the study, the sample of patients is planned to increase to identify characteristic patterns of changes in eye movements when performing cognitive tasks, both in healthy individuals and in patients with cognitive impairment caused by various nervous system diseases.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"13-20"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Proinflammatory cytokines - as a marker of the effectiveness of neuroprotection in children with perinatal nervous system damage].","authors":"V G Degtyareva, V A Drobyshev","doi":"10.17116/jnevro202512506162","DOIUrl":"https://doi.org/10.17116/jnevro202512506162","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of complex rehabilitation measures using the peptidergic drug Cortexin in children with perinatal CNS damage based on the study of serum levels of proinflammatory cytokines.</p><p><strong>Material and methods: </strong>146 children (86 boys, 60 girls) aged from 20 days to 6 months (the average age of boys was 2.7±1.2, and girls 2.9±1.1 months) with CNS PP were examined. Depending on the severity of CNS PP, patients were divided into 3 groups: the 1^st (<i>n</i>=50) included patients with severe CNS PP, the 2^nd (<i>n</i>=58) - moderate and the 3^rd (<i>n</i>=38) - with mild severity. By random sampling, each group was divided into 2 subgroups: patients of subgroups 1A, 2A, and 3A were prescribed Cortexin in addition to standard therapy in accordance with current clinical guidelines. Patients in subgroups 1B, 2B, and 3B received only standard therapy. During the treatment, the concentration of TNF-α and IL-Iß in the blood serum was determined.</p><p><strong>Results: </strong>In subgroup 1A, the concentration of IL-Iß decreased by 1.5 times after treatment (<i>p</i>=0.022), and TNF-α by 1.4 times (<i>p</i>=0.033), which was statistically significantly higher than the similar changes in subgroup 1B. In subgroup 2A, the concentration of IL-Iß decreased by 1.4 times, TNF-α by 1.2 times (<i>p</i>=0.038) by 3 months (<i>p</i>=0.037) from baseline values, whereas in patients of subgroup 2B, no correction of cytokine levels was observed. In subgroup 3A, the dynamics of IL-Iß and TNF-α concentrations had a positive trend and exceeded similar indicators in subgroup 3B.</p><p><strong>Conclusions: </strong>In patients with CNS ASD of varying severity, the inclusion of Cortexin in treatment regimens leads to a significant shift in IL-Iß and TNF-α levels 3 months after the start of treatment, which significantly exceeds the results of standard treatment.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"62-66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Features of care of patients with cardiovascular diseases and cognitive disorders].","authors":"S V Litvinova, A I Kochetkov, O D Ostroumova","doi":"10.17116/jnevro202512506199","DOIUrl":"https://doi.org/10.17116/jnevro202512506199","url":null,"abstract":"<p><p>Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"99-104"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial].","authors":"M N Kalinin, D R Khasanova","doi":"10.17116/jnevro202512506184","DOIUrl":"10.17116/jnevro202512506184","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of Cerebrolysin on brain microstructural integrity and blood-brain barrier (BBB) permeability, as well as their longitudinal changes, using diffusion tensor imaging (DTI) and perfusion computed tomography (PCT) in patients with acute ischemic stroke (AIS).</p><p><strong>Material and methods: </strong>This analysis included patients from the multimodal brain imaging subgroup of the prospective CEREHETIS trial (ISRCTN87656744) with AIS in the middle cerebral artery territory. The intervention group (IG, <i>n=</i>16) received Cerebrolysin in combination with intravenous thrombolysis (IVT) and standard care, while the control group (CG, <i>n=</i>17) received IVT and standard care alone. Brain imaging was performed at 24 hours and on day 14 post-IVT. DTI metrics included axial diffusivity (AD), radial diffusivity (RD), mean diffusivity (MD; 10^-⁶ mm²/s), and fractional anisotropy (FA; ·10^-4) assessed within the infarct core and contralateral region. BBB permeability (PS; mL/100 g/min) was measured on day 14 using PCT. Infarct volume (mL) was determined by diffusion-weighted imaging at 24 hours and by non-contrast CT on day 14. Mixed-effects linear regression models accounting for repeated measures were used to evaluate treatment effects over time, incorporating clinical and imaging predictors, timepoints, and interaction terms.</p><p><strong>Results: </strong>At 24 hours, no significant differences in imaging parameters were observed between groups. By day 14, the IG exhibited significantly higher values of AD (predicted marginal contrast: 259.05; 95% CI 142.19-375.91; <i>p</i><0.001), RD (209.89; 95% CI 106.91-312.87; <i>p</i><0.001), and FA (185.13; 95% CI 22.88-347.37; <i>p</i>=0.021), alongside lower PS values (-1.41; 95% CI -1.69 to -1.13; <i>p</i><0.001) and smaller infarct volume (-6.98; 95% CI -10.13 to -3.82; <i>p</i><0.001). The severity of ischemic injury and functional outcomes were largely influenced by the baseline condition of brain tissue and BBB integrity.</p><p><strong>Conclusion: </strong>Cerebrolysin treatment was associated with favorable changes in quantitative imaging biomarkers, indicating better preservation of brain microstructure, stabilization of BBB permeability, and a reduction in infarct volume in patients with AIS. These findings support the potential cytoprotective effects of Cerebrolysin and highlight the utility of DTI and PCT for evaluating therapeutic efficacy and guiding individualized neuroprotective strategies.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"84-98"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Adolescent suicide risk assessment using the Suicide Risk Rapid Survey].","authors":"A Ya Basova, N A Polskaya, P V Bezmenov, A Yu Razvaliaeva","doi":"10.17116/jnevro202512503186","DOIUrl":"https://doi.org/10.17116/jnevro202512503186","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of the new Suicide Risk Rapid Survey diagnostic scale, which includes six items on suicidal and non-suicidal self-injurious behavior and is aimed at assessing suicide risk in adolescents with suicidal behavior.</p><p><strong>Material and methods: </strong>The psychometric verification of the scale was carried out on a sample of adolescents 10-17 years old (<i>n</i>=114, mean age 14.29±1.66) who were treated in a psychiatric hospital. The following methods were used to check the convergent validity of the scale: Columbia Suicide Severity Rating Scale, Beck Hopelessness Scale, and Beck Scale for Suicidal Ideation.</p><p><strong>Results: </strong>The scale showed satisfactory internal validity (0.7), significant associations with the scales of depression, hopelessness, and suicidal ideation (<i>p<</i>0.001), as well as very high sensitivity (ability to identify patients with suicidal attempts correctly).</p><p><strong>Conclusion: </strong>The satisfactory psychometric characteristics of the Suicide Risk Rapid Survey scale support its use in clinical practice as a tool for rapid assessment of suicide risk in adolescents.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3","pages":"86-93"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of the new coronavirus infection COVID-19 on the course and prognosis of tuberculous meningoencephalitis in HIV-infected patients].","authors":"A A Savin, E B Tsomaeva, A V Bugun, S P Sergeeva, M R Zyuzya, L A Savin, E Yu Romanova, O A Girusova","doi":"10.17116/jnevro202512503133","DOIUrl":"https://doi.org/10.17116/jnevro202512503133","url":null,"abstract":"<p><strong>Objective: </strong>To study the effect of the new coronavirus infection COVID-19 on the course and prognosis of tuberculous meningoencephalitis in HIV-infected patients.</p><p><strong>Material and methods: </strong>The main group included 46 patients with human immunodeficiency virus (HIV) and tuberculous meningoencephalitis who were infected with a new coronavirus infection. The comparison group included 52 patients with tuberculous meningoencephalitis and HIV who had no history of the new coronavirus infection. All patients underwent laboratory tests for infectious diseases (including analysis of cerebrospinal fluid (CSF)), parameters of the hemostasis system, CT of the lungs and brain as part of an inpatient examination.</p><p><strong>Results: </strong>The analysis of the obtained data showed that coronavirus infection aggravates the course of tuberculous meningoencephalitis, increases mortality, affects the mechanisms of thanatogenesis, significantly increasing the frequency of multi-organ failure compared to the comparison group. In patients with coronavirus infection, according to the results of computed tomography of the brain, hydrocephalus was recorded more often, mycobacterium DNA was reliably detected in the CSF using polymerase chain reaction, the syndrome of impaired consciousness at presentation was more common, the period from admission to death was significantly reduced.</p><p><strong>Conclusion: </strong>New data were obtained, suggesting correlations between the combination of manifestations of tuberculous meningoencephalitis, HIV, and coronavirus infection with acute toxic-infectious encephalopathy syndrome, as well as the role of DIC syndrome, which is common in this category of patients.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3","pages":"33-38"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[New opportunities for therapy of adjustment disorder in combat participants: results of a study on the domestic drug Aviandr].","authors":"A V Esipov, M A Samushiya, A F Ivolgin, M R Khommyatov, A Yu Kozachuk, I A Elina, I V Eremitsky, E D Kochereva, M A Koveshnikov","doi":"10.17116/jnevro202512503162","DOIUrl":"https://doi.org/10.17116/jnevro202512503162","url":null,"abstract":"<p><strong>Objective: </strong>To examine the clinical-psychopathological structure of adjustment disorders among sanitary losses of military personnel receiving medical care in a multidisciplinary military hospital, assessing the effectiveness of therapy for adjustment disorder symptoms with the drug Aviandr.</p><p><strong>Material and methods: </strong>A single-center experimental uncontrolled study was conducted, involving 60 patients diagnosed with F43.2 - adjustment disorder; all patients were combat participants.</p><p><strong>Results: </strong>The structure of adjustment disorders in the military personnel group was characterized by the predominance of an anxiety symptom complex; significant contributions to the disorder's structure also included depressive symptoms, dysphoria, and individual PTSD symptoms. Patients with spinal injuries and limb amputations experienced persistent pain syndrome resembling neuropathic and phantom pain. All patients received therapy with Aviandr at a dose of 10 mg twice daily for the first week, followed by an increase to 20 mg twice daily for the next three weeks. A statistically significant reduction in anxiety (<i>p</i>≤0.05) and post-traumatic stress symptoms was observed on the DTS, HARS, GAD-7, Likert scales scores and subjective assessments of state dynamics. In the group of patients with pain syndrome, the reduction in VAS scores was statistically significant but clinically insignificant.</p><p><strong>Conclusion: </strong>The drug Aviandr demonstrated a significant clinical effect in this patient group with a high safety and tolerability profile, making it a potential option for the rapid and effective stabilization of the mental state of military personnel with acute stress-associated disorders.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3","pages":"62-69"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The experience of diagnosing Alzheimer's disease based on the study of cerebrospinal fluid biomarkers].","authors":"K V Nevzorova, Y A Shpilyukova, E Yu Fedotova, A G Burmak, A A Shabalina, S N Illarioshkin","doi":"10.17116/jnevro202512501191","DOIUrl":"10.17116/jnevro202512501191","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the frequency of Alzheimer's disease (AD) confirmed by cerebrospinal fluid (CSF) biomarkers in a cohort of patients with classical (amnesic) and atypical phenotypes of this disease.</p><p><strong>Material and methods: </strong>The study included 63 patients (24 men and 39 women; median age 65 years [60; 71]). All patients were divided into 3 groups according to the phenotype: a classic amnesic phenotype (<i>n=</i>32), frequent non-amnesic phenotypes (<i>n=</i>21) and rare non-amnesic phenotypes (<i>n=</i>10). All patients underwent lumbar puncture followed by the CSF biomarkers evaluation (beta-amyloid 1-42 (Aβ1-42) and phosphorylated tau protein 181 (<i>p-</i>tau181)) to confirm the AD pathology. The clinical characteristics of each subgroup were studied.</p><p><strong>Results: </strong>A decreased level of CSF Aβ1-42 in combination with an increased level of <i>p-</i>tau181 was found in 36 patients (57.1%). A change in at least one biomarker was detected in 54 patients (85.7%). The highest frequency of the Alzheimer's type pathology was found in the group with predominant amnestic phenotype (87.5%), as well as in the subgroups with logopenic variant of primary progressive aphasia (lvPPA) (100%) and with posterior cortical atrophy (PCA) (100%). In the group with rare phenotypes, the frequency of AD CSF changes characteristic of AD was 50% for patients with predominant behavioral disorders and 66.7% for corticobasal syndrome.</p><p><strong>Conclusion: </strong>The high frequency of AD CSF biomarkers in both the classical (amnesic) and atypical phenotypes is shown. This indicates the need to expand the use of AD CSF biomarkers for a more reliable assessment of the prevalence of AD In Russia.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 1","pages":"91-97"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}